Prime-boost immunization with ChAd63/MVA ME-TRAP generated high levels of effector CD4 and CD8 T cell responses [55] and in phase 1/2a clinical trials elicited immune protection from heterologous sporozoite challenge in 21% and delayed time to blood stage parasitemia in 36% of the immunized volunteers [54]. The gene discussed is CD8A; the disease is parasitic infectious disease.